{"id": "367939", "url": "https://fevir.net/resources/Evidence/367939", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"], "versionId": "26", "lastUpdated": "2025-08-18T13:22:42.074Z"}, "name": "NCT03640312_otherOutcomeMeasure_6_OG000", "title": "Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367939. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367939. Computable resource at: https://fevir.net/resources/Evidence/367939#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "statistic": [{"quantity": {"unit": "mg/dL", "value": -0.04}, "sampleSize": {"knownDataCount": 32}, "statisticType": {"coding": [{"code": "STATO:0000573", "system": "https://fevir.net/sevco", "display": "mean"}]}, "attributeEstimate": [{"type": {"text": "Standard Deviation"}, "quantity": {"unit": "mg/dL", "value": 0.11}}]}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "367939", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-6--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Evidence", "variableDefinition": [{"note": [{"text": "Outcome Measure Population Description: Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol."}, {"text": "Outcome Measure Denominator Units: Participants"}], "observed": {"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.", "identifier": {"type": {"text": "ClinicalTrials.gov Outcome Measurement Group Id"}, "value": "OG000"}}, "description": "QUARTET LDQT", "variableRole": "population"}, {"observed": {"type": "EvidenceVariable", "display": "Mean Change in Serum Creatinine at 12 weeks -  (NCT03640312)", "reference": "EvidenceVariable/367902", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-6", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "outcome"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}